How we treat primary central nervous system lymphoma

T. Calimeri1, S. Steffanoni1, F. Gagliardi2, A. Chiara3 & A. J. M. Ferreri1*

1 Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan; 2 Department of Neurosurgery and Gamma Knife Radiosurgery, San Raffaele Scientific Institute, Vita-Salute University, Milan; 3 Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy

Available online 13 July 2021

Primary diffuse large B-cell (DLBCL) lymphoma of the central nervous system (CNS) (PCNSL) is a new lymphoma entity, recognized by the 2017 WHO classification of hematopoietic and lymphoid tumors. Unlike systemic DLBCL, the use of anthracycline-based chemotherapy combinations is associated with disappointing outcomes, due to low CNS bioavailability of related drugs. Therefore, international researchers investigated alternative strategies, mostly including drugs able to cross the blood—brain-barrier at low or high doses, with a progressive improvement in survival. Some effective chemotherapy combinations of high-dose methotrexate (HD-MTX) with alkylating agents and rituximab with or without cytarabine have been tested in international randomized trials and represent the induction treatment in everyday practice, with some variations among different geographical areas. In patients aged 70 years or younger, MATRix (HD-MTX/cytarabine/thiotepa/rituximab) chemotherapy followed by consolidative high-dose chemotherapy plus autologous stem cell transplantation or whole-brain irradiation has been associated with a significant improvement in overall survival. Other treatment options, such as non-myeloablative high-dose chemotherapy, oral drug maintenance, and some targeted drugs like ibrutinib or lenalidomide, are being tested in high-level international trials. These steps toward further effective treatments are motivated by an incessant search for less neurotoxic options. Thanks to international cooperation, we can affirm that PCNSL is a potentially curable tumor, especially in young patients. However, several questions remain unanswered: the optimal treatment for elderly patients as well as the management of intraocular and meningeal disease require further scientific efforts. Beside treatments, advances on molecular and radiological diagnostic tools will increase our knowledge of this disease, allowing the possibility to anticipate diagnosis and to better categorize patients’ responses. This article analyzes the available literature in this setting and provides evidence-based recommendations for the management of PCNSL patients.

Key words: primary CNS lymphoma, primary vitreoretinal lymphoma, high-dose methotrexate, lenalidomide ibrutinib

A SHORT LOOK TO EPIDEMIOLOGICAL AND HISTORICAL DATA

Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) (PCNSL) is a rare and aggressive lymphoproliferative disease that was recently recognized as a distinct entity by the 2017 World Health Organization classification of hematopoietic and lymphoid tumors.1 PCNSL accounts for 4% of primary CNS neoplasms and 4%-6% of extranodal lymphomas. New cases are generally diagnosed in the fifth or sixth decade of life, and with a slightly higher frequency among males.2 Except for immunosuppression status, no other risk factors predisposing the development of PCNSL are known.

PCNSL FIRST LOOK: A MULTIDISCIPLINARY APPROACH

Management of patients with newly diagnosed PCNSL is complex and requires a multidisciplinary approach (Table 1). Clinical presentation of PCNSL is heterogeneous and depends on the involved CNS structures that could include brain, leptomeninges, eyes, cranial nerves, and spinal cord. Symptoms are mainly focal neurological deficits, personality changes, and increased intracranial pressure, and usually require immediate evaluation by neurologists and/or neurosurgeons, with a subsequent neuroimaging examination. Contrast-enhanced brain magnetic resonance imaging (MRI) (bMRI) is the best modality option for assessing PCNSL patients. Lesions are often isointense/hypointense on T2-weighted MRI, with surrounding edema.
and a homogeneous and strong pattern of enhancement. PCNSL presents as a solitary lesion in 60%-70% of cases, mostly located in the hemispheres, basal ganglia, corpus callosum, and periventricular regions. It tends to infiltrate the subependymal tissues and disseminates through the cerebrospinal fluid (CSF) to the meninges, which is often asymptomatic and detectable by cytology/ immunophenotypic analysis on CSF in 16% of cases. Some patients (10%-20%) experience visual complaints (i.e., floaters, blurred vision, visual field defects, and decrease in vision) as initial and often exclusive symptoms. This alternative presentation needs to be taken into account in the differential diagnosis of the ‘masquerade syndromes’ from an expert ophthalmologist who will confirm the presence of intraocular disease. An accurate staging disease aims both to define the extension of disease in different CNS structures and to rule out concomitant systemic lymphoma. Conventional staging with \(^{18}\text{F}2\)-fluoro-2-deoxy-D-glucose positron emission tomography (\(^{18}\text{FDG}-\text{PET}\)), bone marrow biopsy/aspiration and testicular ultrasound, detects extra-CNS disease in 4%-12% of patients with presumptive diagnosis of PCNSL. Although it is used as a fast and sensitive procedure to exclude systemic disease during staging, \(^{18}\text{FDG}-\text{PET}\) plays a limited role to assess PCNSL lesions and response to treatment, mostly due to physiologic tracer accumulation in the brain. Recently, the novel PET tracer \(^{68}\text{Ga}\)Ga-PentixaFor, used for the visualization of C-X-C chemokine receptor 4 (CXCR4)-positive malignancies, showed interesting applicability in both visualization and treatment response assessment of CNS lymphoma.\(^3\) Prospective assessment of this new theranostic agent in PCNSL is warranted. At presentation, most PCNSL patients receive immediate steroid therapy with fast symptomatic improvement and radiographic regression in ~40% of patients. Mass shrinking can interfere with histopathologic diagnosis; for this reason the use of steroids should be limited to cases of osmotherapy inef

### CRITERIA CONDITIONING THE CHOICE OF TREATMENT

#### Patient stratification

The multidisciplinary team devoted to the management of PCNSL patients at our institution has extensive experience in clinical research, leading several clinical studies in this field. Accordingly, when faced with a patient with a new diagnosis of PCNSL, our first thought is to enroll him/her in a prospective trial. The following concepts regard our therapeutic choices for PCNSL patients managed outside prospective trials (Figure 1).

Age and performance status (PS) are important prognostic factors; however, several other details, like comorbidity, organ function, frailty, and risk of neurotoxicity, should be considered in the choice of the better treatment. In prospective trials, age cut-off used to define young patients varied between 60 and 75 years. In routine practice, patients aged between 60 and 75 years often receive personalized treatment because of large variability in comorbidity and neurological conditions. Thus, in this population, we consider suitability to receive high dose chemotherapy plus autologous stem cell transplantation (HDC/ASCT) as the main parameter to distinguish ‘young-fit’ and ‘elderly-frail’ patients.

#### How we treat young, fit patients

The modern treatment of PCNSL includes two phases: induction and consolidation. Thus, based on the results of the IELSG32 trial,\(^5\) polychemotherapy with four cycles of the MATRix regimen [methotrexate (MTX), cytarabine, thiotepa, rituximab] followed by HDC/ASCT is the preferred treatment option for young patients without severe comorbidities. Peripheral autologous hematopoietic stem cells (HSC) are usually collected after the second cycle. Patients with responsive disease according to International Primary CNS Lymphoma Collaborative Group criteria\(^6\) are consolidated with ASCT using a conditioning regimen with carmustine and thiotepa.\(^5\) Our standard choice of MTX dose and administration schedule, that is 3.5 g/m² in a 3-h infusion, is based on well-documented higher response rate and CSF levels. In the case of dose reductions due to toxicity, we try to deliver a dose of 3 g/m² (85%) to not compromise CNS penetration, maintaining tumoricidal levels in the brain parenchyma and CSF. MATRix includes rituximab, the role of which in PCNSL treatment is a matter of debate. At the time to design the IELSG32 study, the results of the HOVON 105/ALLG NHL 24 randomized trial were not available. The latter was focused on the role of rituximab in PCNSL patients aged 18-70 years, demonstrating a near significant benefit in patients younger than 60 years.\(^7\) Conversely, an effect in patients older than 60 years was not demonstrated, probably because these patients did not receive consolidation radiotherapy, with consequent disappointing...
survival figures, which probably hampered a benefit from this antibody. Moreover, the long-lasting results of the IELSG32 trial (after a median follow-up of 88 months) that demonstrate a significantly better progression-free survival (PFS) and overall survival in patients treated with rituximab, and the recent report that this drug does not affect cognitive functions prompt us to confirm our choice to keep rituximab as part of the MATRix combination.

Disease evaluation with bMRI is carried out after the second and fourth cycle of MATRix as well as after 2-3 months from ASCT. Eye and CSF assessments are carried out at the same time points in case of ocular and/or meningeal involvement at diagnosis, otherwise they are done at the end of the whole treatment or in case of clinical suspicion. In case of disease persistence in the vitreo-retinal compartment at the end of systemic therapy, indication to intravitreal treatment with rituximab 0.5 mg/0.1 ml and MTX 0.4 mg/0.1 ml is discussed with the ophthalmologist. Leptomeningeal relapse is an uncommon event in PCNSL patients treated with a modern approach. Accordingly, and in line with recently reported and ongoing international trials, we do not use intrathecal chemotherapy as part of first-line treatment.

Whole brain radiotherapy (WBRT) is an alternative to ASCT in case of HSC harvest failure or complications during induction. WBRT is not our first choice as consolidation therapy due to the increased risk of impairment of cognitive functions demonstrated in the IELSG32 and the PRECIS trials. The rehabilitative program is an important support for the recovery of these patients; thus, it is planned starting from the beginning of the induction therapy. Neuropsychological tests are usually carried out at diagnosis and at the end of first-line therapy, and used as baseline data to monitor any potential cognitive decline during follow-up.

How we treat elderly or frail patients

Most patients older than 70 years are not eligible for ASCT, and should be stratified according to the suitability to receive HD-MTX-based chemotherapy (Figure 1). Patients with normal renal function, adequate bone marrow reserve,
and preserved cardiac function (ventricular ejection fraction \( \geq 45\% \), no recent acute coronary artery disease or uncontrolled arrhythmias) are good candidates for this treatment. A combined treatment with HD-MTX, an alkylating agent (i.e. procarbazine, temozolomide) and rituximab is recommended. In responding patients, low-dose WBRT (23.4 Gy) consolidation or maintenance with oral alkylating agents should be considered. According to multicenter retrospective experience, selected patients older than 70 years with good PS and suitable organ function may be candidates for HDC/ASCT. For these patients, we consider MATRix at 25% reduction dose as induction before carmustine-thiotepa-conditioned ASCT (Figure 1).

Primary WBRT is an option for unfit patients not eligible for HD-MTX, with a 2-year PFS of 30%. As for high-grade gliomas, some investigators suggested adding concomitant and maintenance temozolomide, but this remains an experimental approach. Occasionally, unfit patients are referred to exclusive palliative care and, in this case, indication to brain biopsy should be discussed with caregivers.

**How we treat patients with relapsed or refractory disease**

A standard of care for patients with relapsed or refractory PCNSL remains to be established. Clinical trials should be the preferred treatment option because this is the best strategy to identify new active drugs and strategies that could be subsequently investigated as part of first-line therapy. When a prospective trial is not available, therapeutic choice should be based on published phase II trials. In case of late relapse (\( >24 \) months) and previous response to HD-MTX-based regimens, HD-MTX re-challenge is a safe and effective strategy. In earlier relapses, we prefer to use high-dose ifosfamide-containing regimens, in particular the R-IE (rituximab/ifosfamide/etoposide) regimen, which is associated with a 38% overall response rate (ORR) and a 2-year survival after relapse of 25%. In both early and late relapses, we recommend a subsequent consolidation or maintenance therapy, the choice of which depends on previous treatments, availability of autologous HSC, comorbidity, and the patient’s general condition.

Besides chemotherapy combinations, new drugs are being investigated with promising results. The mechanistic target of rapamycin (mTOR) inhibitor temsirolimus has been demonstrated to confer an ORR of 54% in a heavily pretreated, elderly population; however, its use is limited by a considerable toxicity and treatment-related mortality of 13.5%. The first-in-class Bruton tyrosine kinase inhibitor ibrutinib has been investigated as a single agent or in combination with chemotherapy in patients with CNS lymphoma revealing fast and impressive responses. At a flat dose of 560 mg daily, ibrutinib has been associated with an ORR of 50%, and dose escalation until 840 mg resulted in a 77% ORR. Ibrutinib achieved adequate CSF concentration with a safe profile; however, an increased incidence of invasive aspergillosis has been reported (up to 39% of patients), but a timely interruption or omission of steroid therapy might prevent this severe complication. Immuno-modulatory drugs (lenalidomide and pomalidomide) have been investigated in patients with relapsed or refractory PCNSL or primary vitreoretinal lymphoma achieving an objective response in half of the patients, but the response was usually short lived. Lenalidomide, used as single agent at low dose (5-10 mg) as maintenance therapy and in combination with rituximab, deserves to be further

**Figure 1. Therapeutic flow chart.**

HDC/ASCT, high dose chemotherapy plus autologous stem cell transplantation; HD-MTX, high dose methotrexate; MATRix, high dose methotrexate, cytarabine, thiotepa, rituximab; PCNSL, primary central nervous system lymphoma; PS, performance status; WBRT, whole brain radiotherapy.
investigated in this setting. At the moment, we do not use anti-programmed cell death protein 1 antibodies because results of phase II trials are pending.

Anti-CD19 chimeric antigen receptor (CAR)-T cells were recently approved for the treatment of relapsed/refractory DLBCL, with promising results in other B-cell lymphomas. This approach deserves to be addressed in patients with relapsed or refractory PCNSL considering its encouraging preliminary results reported in patients with secondary CNS DLBCL.

ACKNOWLEDGEMENTS
We are indebted to our patients and their families for their generous commitment. We particularly thank hematologists, oncologists, neuroradiologists, pathologists, neurosurgeons, ophthalmologists, radiation oncologists, and psychologists at IRCCS San Raffaele Scientific Institute for the sustained clinical and scientific collaboration. We thank all the nurses for the clinical assistance and appreciate the excellent technical support of our study coordinator office.

FUNDING
None declared.

DISCLOSURE
TC: funding from Roche; other: Sandoz. AJMF: speaker fee from Adienne; research grants from Bristol-Myers Squibb, Beigene, Pharmacyclics, Hutchison Medipharma, Amgen, Genmab, ADC Therapeutics, Gilead, Novartis, and Pfizer; advisory boards from Gilead, Novartis, Juno, and Pletix-aPharm; inventor of patents on NGR-hTNF/RCHOP in relapsed or refractory PCNSL and SNGR-hTNF in brain tumors. All other authors have declared no conflicts of interest.

REFERENCES